Changes of central macular thickness post intravitreal ranibizumab and its associated factors among diabetic macular oedema patients
Background: Intravitreal Ranibizumab (IVR) which is an anti-vascular endothelial growth factor (anti-VEGF) has become the preferred treatment option to improve the vision of diabetic macular oedema (DMO) patients. IVR acts by inhibits VEGF-A from binding to its receptors, leading to decreased in vas...
Saved in:
Main Author: | Tahir, Nursyafiqah Md |
---|---|
Format: | Thesis |
Language: | English |
Published: |
2020
|
Subjects: | |
Online Access: | http://eprints.usm.my/51000/1/Nursyafiqah%20Md%20Tahir-24%20pages.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy of intravitreal triamcinolone versus aser photocoagulation in the primary treament of diabetic macular oedema
by: Mustafa, Norlaili
Published: (2008) -
Evaluation of visual acuity and macular thickness post focal laser with and without supplementary honey in diabetic macular oedema
by: Rahim, Raihan Abd
Published: (2016) -
Quality of life of patients with neovascular age-related macular degeneration after treatment with intravitreal ranibizumab /
by: Safiyah Jameelah Mohd Yusof
Published: (2016) -
Effect of intravitreal triamcinolone acetonide on patients with diabetic macular edema unresponsive to macular laser /
by: Yip, Chee wai
Published: (2005) -
The efficacy of intra vitreal triamcinolone versus laser
photocoagulation in the primary treatment of
diabetic macular oedema
by: Norlaili, Mustafa
Published: (2008)